Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf you've searched for a weight loss injection consultation, you've probably already read that you need one — but fewer sources explain what it actually consists of or why it matters clinically. The consultation is a full medical assessment, not a formality. A prescriber reviews your health, medications, BMI, and relevant conditions to decide whether tirzepatide (Mounjaro) or semaglutide (Wegovy) is appropriate for you. These are prescription-only medicines; a genuine clinical assessment is the legal and medical prerequisite for accessing either. Explore how the process works at nume, where every consultation is read and decided by a GPhC-registered Independent Prescriber, not software.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
This is the misconception that causes the most harm. Some sellers market weight loss injections as though the prescription step is an administrative hurdle, something quick and automatic before the real product lands at your door. It isn't. The consultation is where the clinical work happens.
A prescriber is checking things that genuinely affect safety. Your BMI must meet the licensed threshold: 30 or above, or 27 and above if you have a weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnoea. That condition list isn't arbitrary, it's the licensed indication set out in the Mounjaro and Wegovy SmPCs. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance, which a prescriber will account for.
Beyond the threshold, your prescriber looks at your current medications, because GLP-1 medicines slow gastric emptying and that affects how other drugs are absorbed. They check for contraindications, a personal or family history of medullary thyroid carcinoma, certain pancreatic conditions, or serious GI disease. They ask about contraception: women taking oral contraceptives starting tirzepatide are advised to add a non-oral method for the first four weeks of treatment and after each dose increase, because pill absorption may be reduced. None of this is a formality. It's a medical assessment that protects you.
If you want a clearer picture of the genuine risks and downsides of weight loss injections, that context sits alongside the consultation process, both matter.
A proper weight loss injection consultation in the UK isn't a five-question tick-form. It covers your current weight and height (to calculate BMI), your medical history, any relevant conditions, your current and recent medications, your goals, and your understanding of what treatment involves. At nume (sorry, at a regulated service) identity verification and live weight confirmation are part of the process too, because dose-escalation decisions depend on documented progress, not self-reported numbers.
The MHRA's public guidance on GLP-1 medicines for weight loss is clear that these medicines are not assessed or licensed for quick or cosmetic weight loss; they're for adults with clinical obesity or excess weight alongside a health condition. A prescriber who doesn't ask about your health conditions isn't doing a consultation, they're issuing paper.
At nume, a GPhC-registered Independent Prescriber reads your answers and decides the same day. If you order before 12pm on a weekday (handy if payday lands on a Monday and you want things moving quickly) clinically approved treatment is dispatched the same day and delivered free the next working day by DPD, in plain packaging. No subscription, no auto-renewal; every repeat order gets the same clinical review.
The full step-by-step route to getting weight loss injections through a regulated pharmacy covers this sequence in more detail.
The initial consultation is the start, not the whole story. Both Mounjaro and Wegovy begin at a low starter dose (Mounjaro at 2.5mg, Wegovy at 0.25mg) not because these doses produce significant weight loss on their own, but because your system needs time to adjust and tolerability matters. The dose increases over weeks and months under prescriber guidance.
That ongoing review is part of legitimate treatment. The NHS England guidance on weight management injections notes that both diet and physical activity support should accompany the medicine, and that progress should be monitored. For tirzepatide, NICE recommends reassessing if fewer than 5% of body weight is lost after six months at the highest tolerated dose.
Common side effects during treatment are mostly gastrointestinal: nausea, loose stools, constipation, indigestion, and fatigue are all documented. Constipation in particular is something patients sometimes underestimate going in. These effects tend to peak when a dose increases and ease off within a week or two for most people, but the prescriber needs to know if they don't.
There's also a category of symptoms that needs urgent medical attention rather than a message to your pharmacy. The MHRA issued a Drug Safety Update in January 2026 specifically highlighting acute pancreatitis with GLP-1 medicines: severe, persistent abdominal pain, especially if it radiates to the back, is a reason to seek medical help promptly. For a full picture of what to watch for, the weight loss injection overview covers the safety profile in detail. Side effects can also be reported directly at the MHRA's Yellow Card scheme.
Treatment involves used needles, which need safe disposal, a sharps container is the correct way to handle them and is often something patients arrange before their first pen arrives.
Sellers offering weight loss injections without a prescription, through social media, or at prices well below the market rate are a documented public health problem. The MHRA has made large seizures of counterfeit and illegally traded weight-loss pens, including fake tirzepatide products found in unlicensed UK manufacturing. Some seized fakes have contained insulin rather than the labelled medicine. A consultation-free route isn't a faster route to genuine treatment, it's the route to an unverified product from an unverified source.
You can check any online pharmacy against the GPhC register at the GPhC's public register, that link goes directly to the entry for nume's pharmacy. A registered premises number, a named prescriber, and a real clinical process are the baseline, not extras.
The cost of a consultation (whether that's time or money) is the cost of doing this safely. An overview of weight loss injections in the UK sets out the landscape for anyone still weighing up their options, and if you're based in the area and want local context, our weight loss injections reno page covers what the process looks like for patients there. If you're ready to take the next step, start your free consultation with nume and a prescriber will review your case the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.